

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6947714

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
RAYMOND KOZIKOWSKI III	09/29/2021
MARIAN MIKAELA RYGELSKI	09/30/2021
MATTHEW THURMAN	09/29/2021
RECEIVING PARTY DATA	
Name:	VENTANA MEDICAL SYSTEMS, INC.
Street Address:	1910 E. INNOVATION PARK DRIVE
City:	TUCSON
State/Country:	ARIZONA
Postal Code:	85755
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15987799
CORRESPONDENCE DATA	
Fax Number:	(925)225-1128
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	925-251-6812
Email:	erica.layman@roche.com
Correspondent Name:	ERICA LAYMAN
Address Line 1:	4300 HACIENDA DRIVE
Address Line 2:	PATENTS
Address Line 4:	PLEASANTON, CALIFORNIA 94588
ATTORNEY DOCKET NUMBER:	33348-US1
NAME OF SUBMITTER:	ADEN A. REHMS
SIGNATURE:	/Aden A. Rehms/
DATE SIGNED:	10/01/2021
Total Attachments: 9	
source=33348-US1 Assign Inv to VMSI 15987799 complete#page1.tif	
source=33348-US1 Assign Inv to VMSI 15987799 complete#page2.tif	
source=33348-US1 Assign Inv to VMSI 15987799 complete#page3.tif	

source=33348-US1 Assign Inv to VMSI 15987799 complete#page4.tif
source=33348-US1 Assign Inv to VMSI 15987799 complete#page5.tif
source=33348-US1 DocuSign Sumary Dec_Assign#page1.tif
source=33348-US1 DocuSign Sumary Dec_Assign#page2.tif
source=33348-US1 DocuSign Sumary Dec_Assign#page3.tif
source=33348-US1 DocuSign Sumary Dec_Assign#page4.tif

*Docket No. P33348-US1***ASSIGNMENT**

We,

Raymond Kozikowski III, of Tucson, Arizona, U.S.A.,
Marian Mikaela Rygelski, of San Francisco, California, U.S.A., and
Matthew Thurman, of Tucson, Arizona, U.S.A.

(hereinafter "Assignors"), while employed by Ventana Medical Systems, Inc., having a place of business at 1910 E. Innovation Park Drive, Tucson, Arizona 85755

have invented one or more inventions which are at least as embodied in:

Roche Ref. No.	Country	Application Number	Application Date
33348-US1	United States	15/987,799	23 May 2018

Entitled: FLUID COVERAGE SENSING SYSTEM AND METHOD

which application is referred to herein as the "Patent Application" which claims priority to and the benefit of:

Roche Ref. No.	Country	Application Number	Application Date
33348-WO	Patent Cooperation Treaty	PCT/EP2016/079547	02 Dec 2016
33348-US	United States	62/262,855	03 Dec 2015

collectively, the "Invention."

In consideration of our obligations and other valuable consideration constituting adequate and full compensation, we each hereby sell, assign, and transfer to Ventana Medical Systems, Inc., its successors and assigns (collectively, "Assignee"), each of our respective full and exclusive right, title, and interest in the Invention, the Patent Application, and any corresponding patent rights throughout the United States and its territories and dependencies, and all other countries and jurisdictions of the world, or hereby acknowledge the previous transfer to Assignee of all such right, title and interest in the Invention, the Patent Application, and any corresponding patent rights throughout the United States and its territories and dependencies, and all other countries and jurisdictions of the world. The conveyance of patent rights includes, without limitation, full and exclusive right, title, and interest in all nonprovisional patent applications claiming all or part of the Invention and/or claiming the benefit of a filing date of the Patent Application, and any patents that may issue from any divisional, continuation, continuation-in-part, substitution, conversion, re-examination, reissue, renewal, prolongation or extension thereof; and the right to claim priority from the Patent Application as provided for by United States law, the Patent Cooperation Treaty, the European Patent Convention, the Paris Convention, or other applicable law.

The Invention was made as a result of our activities at or on behalf of Assignee or as a result of our utilization of information, facilities or other resources of Assignee. The conditions under which the Invention was made are such as to entitle Assignee under the applicable law to each of our entire respective right, title, and interest in the Invention and any corresponding patent applications and/or

Docket No. P33348-US1

patents in the United States and its territories and dependencies, and all other countries and jurisdictions of the world.

Assignors each authorize and request the issuance of any patents arising from nonprovisional patent applications claiming all or part of the Invention and/or claiming the benefit of a filing date of the Patent Application to the Assignee to be held as fully and entirely as the same would have been held by us had this assignment not been made.

Assignors each warrant that, to the best of their knowledge, there are no outstanding assignments, grants, liens, encumbrances, or agreements either written, oral, or implied that will impair, diminish, limit, or abridge the interest herein conveyed.

Assignors each also agree upon reasonable request to communicate with the Assignee, its representatives or agents, any facts known to us respecting all or part of the Invention, and testify in any legal proceedings, sign all lawful papers, execute all nonprovisional, divisional, continuation, continuation-in-part, re-examination, and reissue applications, make all rightful oaths, provide all requested documents, and do everything reasonably possible to aid the Assignee, its representatives or agents, to obtain and enforce proper patent protection for all or part of the Invention in the United States or any other country of the world. These provisions are binding upon each of our heirs, legal representatives, administrators and assigns.

The assignment of the rights of any Co-Inventor(s) are subject to separate assignment agreements. Assignors explicitly approve any such assignments.

This Assignment may be executed in one or more counterparts, each of which when executed and delivered, by facsimile or other electronic transmission, by mail delivery, or by other form of delivery, will be an original and all of which will constitute one and the same Assignment.

IN WITNESS WHEREOF, this Assignment is executed as of the date(s) indicated on the following counterpart signature page(s).

REMAINDER OF PAGE INTENTIONALLY BLANK

Docket No. P33348-US1

ASSIGNMENT COUNTERPART SIGNATURE PAGE

Case No.	Country	Application No.	Application Date
33348-US1	United States	15/987,799	23 May 2018
33348-WO	Patent Cooperation Treaty	PCT/EP2016/079547	02 Dec 2016
33348-US	United States	62/262,855	03 Dec 2015

Tucson, AZ
Place: _____
29-Sep-2021
Dated: _____


ASSIGNOR:

DocuSigned by:

C:15A0223F1304BA...
Raymond Kozikowski III

Pleasanton, CA, USA
Place: _____
30-Sep-2021
Dated: _____

ASSIGNEE: Ventana Medical Systems, Inc.

DocuSigned by:

47CEDFA7F40A40A...
Suja Subramaniam
Vice President, Intellectual Property


Docket No. P33348-US1

ASSIGNMENT COUNTERPART SIGNATURE PAGE

Case No.	Country	Application No.	Application Date
33348-US1	United States	15/987,799	23 May 2018
33348-WO	Patent Cooperation Treaty	PCT/EP2016/079547	02 Dec 2016
33348-US	United States	62/262,855	03 Dec 2015


Place: New York, NY
Dated: 30-Sep-2021

ASSIGNOR:

DocuSigned by:

9F7D86E1B1C7485...
Marian Mikaela Rygelski

Place: Pleasanton, CA, USA
Dated: 30-Sep-2021

ASSIGNEE: Ventana Medical Systems, Inc.

DocuSigned by:

4ACEBEA7E10A40A...
Suja Subramaniam
Vice President, Intellectual Property

Docket No. P33348-US1

ASSIGNMENT COUNTERPART SIGNATURE PAGE

Case No.	Country	Application No.	Application Date
33348-US1	United States	15/987,799	23 May 2018
33348-WO	Patent Cooperation Treaty	PCT/EP2016/079547	02 Dec 2016
33348-US	United States	62/262,855	03 Dec 2015

Place: Tucson, AZ, USA
Dated: 29-Sep-2021

ASSIGNOR:

DocuSigned by:
Matthew Thurman
BB50A8076F7C4E9...
Matthew Thurman

Place: Pleasanton, CA, USA
Dated: 30-Sep-2021

ASSIGNEE: Ventana Medical Systems, Inc.

DocuSigned by:
Suja Subramaniam
FACEBFA7F10A10A...
Suja Subramaniam
Vice President, Intellectual Property

Certificate Of Completion

Envelope Id: 087B51B5520D4264B02E5890A9D4F369

Status: Completed

Subject: Please DocuSign: 33348-US1; Inventor Assignment and Declarations

Source Envelope:

Document Pages: 52

Signatures: 9

Envelope Originator:

Certificate Pages: 4

Initials: 0

Erica Layman

AutoNav: Enabled

Grenzachstrasse 124

Enveloped Stamping: Enabled

Basel, Basel-Stadt 4070

Time Zone: (UTC-08:00) Pacific Time (US & Canada)

erica.layman@roche.com

IP Address: 198.21.24.251

Record Tracking

Status: Original

Holder: Erica Layman

Location: DocuSign


9/29/2021 10:48:52 AM

erica.layman@roche.com

Signer Events

Matthew Thurman

Matt.A.Thurman@gmail.com

Security Level: Email, Account Authentication
(None)**Signature**DocuSigned by:

BB59A0075F7C4E9...**Timestamp**

Sent: 9/29/2021 12:20:04 PM

Viewed: 9/29/2021 1:49:59 PM

Signed: 9/29/2021 1:52:44 PM

Signature Adoption: Pre-selected Style

Using IP Address: 174.205.40.59

Signed using mobile

Electronic Record and Signature Disclosure:


Accepted: 9/29/2021 1:49:59 PM

ID: ec92a3a7-94e5-42f5-98d8-dba721da4dc

Company Name: Genentech

Mikaela Rygelski

mikaela.rygelski@roche.com

Security Level: Email, Account Authentication
(None)DocuSigned by:

9F7D9BE1B4C7485...

Sent: 9/29/2021 12:20:04 PM

Viewed: 9/30/2021 8:36:55 AM

Signed: 9/30/2021 8:39:29 AM

Signature Adoption: Drawn on Device

Using IP Address: 69.203.114.11

Electronic Record and Signature Disclosure:


Accepted: 9/30/2021 8:36:55 AM

ID: 00ea6897-0da0-4995-bb57-438380c785be

Company Name: Genentech

Raymond Kozikowski III

raymond.kozikowski.rk1@roche.com

Security Level: Email, Account Authentication
(None)DocuSigned by:

C16A6223F1384BA...

Sent: 9/29/2021 12:20:03 PM

Viewed: 9/29/2021 2:13:28 PM

Signed: 9/29/2021 2:14:03 PM

Signature Adoption: Pre-selected Style

Using IP Address: 73.127.94.226

Electronic Record and Signature Disclosure:


Accepted: 9/29/2021 2:13:28 PM

ID: f31382ed-91fc-46b8-aba1-846fb9673091

Company Name: Genentech

Suja Subramaniam

suja.subramaniam@roche.com

Security Level: Email, Account Authentication
(None)DocuSigned by:

4ACEBFA7F10A40A...

Sent: 9/30/2021 8:39:32 AM

Viewed: 9/30/2021 3:23:06 PM

Signed: 9/30/2021 3:23:45 PM

Signature Adoption: Pre-selected Style

Using IP Address: 98.37.113.99

Signed using mobile

Electronic Record and Signature Disclosure:

Signer Events	Signature	Timestamp
Accepted: 9/30/2021 3:23:06 PM ID: 9d53f896-8fae-4c8e-90b1-6370ebb15e90 Company Name: Genentech		
In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp
Aden Rehms aden.rehms@roche.com Security Level: Email, Account Authentication (None) Electronic Record and Signature Disclosure: Not Offered via DocuSign		<div>COPIED</div> Sent: 9/29/2021 12:20:04 PM
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	9/29/2021 12:20:04 PM
Certified Delivered	Security Checked	9/30/2021 3:23:06 PM
Signing Complete	Security Checked	9/30/2021 3:23:45 PM
Completed	Security Checked	9/30/2021 3:23:45 PM
Payment Events	Status	Timestamps
Electronic Record and Signature Disclosure		

Guidelines for the use of the DocuSign electronic signing system within F. Hoffmann-La Roche and companies of the Roche Group

LEGAL DISCLOSURE

By placing my electronic signature on this document, I expressly consent to use and rely on Electronic and Digital Signatures and I understand my signature will have the same binding effect as if I was providing a handwritten signature.

I also confirm the email address that I am using as a valid one to be notified and identified electronically, for example through the DocuSign System, and/or to identify me as the signer of the document. I should inform Roche in the case that the email address changes.

CONSUMER DISCLOSURE

From time to time, F. Hoffmann-La Roche and companies of the Roche Group (hereinafter referred to as we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign, Inc. (DocuSign) electronic signing system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to these terms and conditions, please confirm your consent by clicking the 'I agree' button at the bottom of this document.

Consequences of changing your mind

To indicate to us that you are changing your mind, you must withdraw your consent using the DocuSign 'Withdraw Consent' form on the signing page of a DocuSign envelope instead of signing it. This will indicate to us that you have withdrawn your consent to receive required notices and disclosures electronically from us and you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact us

You may contact us to let us know of your changes as to how we may contact you electronically, to request certain information from us and to withdraw your prior consent to receive notices and disclosures electronically. To do so contact the sender of the envelope.

To advise us of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to the sender of the envelope and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address. In addition, you must notify DocuSign, Inc. to arrange for your new email address to be reflected in your DocuSign account by following the process for changing email in the DocuSign system.

To withdraw your consent

To inform us that you no longer want to receive future notices and disclosures in electronic format you may decline to sign a document from within your DocuSign session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent.

Acknowledging your access and consent to receive materials electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please verify that you were able to read this electronic disclosure and that you also were able to print on paper or electronically save this page for your future reference and access or that you were able to email this disclosure and consent to an address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format on the terms and conditions described above, please let us know by clicking the 'I agree' button below.

By checking the 'I agree' box, I confirm that:

- I can access and read this Electronic CONSENT TO ELECTRONIC RECEIPT OF ELECTRONIC CONSUMER DISCLOSURES document; and
- I can print on paper the disclosure or save or send the disclosure to a place where I can print it, for future reference and access; and
- Until or unless I notify the account owner as described above, I consent to receive from exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to me by the account owner during the course of my relationship with you.
- I acknowledge the information included in the [DocuSign Privacy Policy](#)